




EVOLVING TECHNOLOGY/BASIC SCIENCEDurable staged hybrid ablation with thoracoscopic and percutaneous
approach for treatment of long-standing atrial fibrillation: A














1460Objectives: Electrophysiologic and surgical procedures to treat stand-alone atrial fibrillation (AF) have recently
evolved, but disappointing results in patients with long-standing persistent (LSP) AF have challenged the dura-
bility of these procedures.
Methods: Lone AF patients (n ¼ 36) with either LSP-AF (n ¼ 28) or persistent AF (n ¼ 8) were prospectively
enrolled in the study and consecutively treated by thoracoscopic ablation followed by electrophysiologic eval-
uation 30 days afterward. Mean left atrial dimension was 50.3  5.5 mm, and average AF duration was 72.8
months (range, 7-240 months). The thoracoscopic procedure was a right monolateral approach to create
a box lesion using a temperature-controlled radiofrequency device with suction adherence. A continuous rhythm
monitoring device was implanted at the end of the operation.
Results: Thoracoscopic ablation was successfully completed without morbidity or mortality and without any
intensive care unit stay. Intraoperative exit and entrance block was achieved in 100% and 88.8% (32/36) of pa-
tients, respectively. At 33 2 days after the operation, an electrophysiologic study confirmed entry–exit block in
83.3% (30/36) whereas pulmonary vein reconnections were observed in 16.7% (6/36) of patients. Additional
transcatheter lesions were performed in 61.1% (22/36) of patients. At a mean follow-up of 30 months (range,
1-58 months), 91.6% (33/36) of patients are in sinus rhythm with 77.7% (28/36) of these patients off antiar-
rhythmic drugs and 88.8% (32/36) free of warfarin. Long-term incidence of left atrial flutter was 0%.
Conclusions: The combination of a surgical box lesion and transcatheter ablation in a hybrid approach provided
excellent durable clinical outcomes in patients with LSP-AF. (J Thorac Cardiovasc Surg 2012;144:1460-5)Surgical and percutaneous approaches have been aiming at
effectively treating atrial fibrillation (AF), with progressive
technical and technologic refinements from either side oc-
curring during the past decade. From the surgical stand-
point, several less-invasive procedures have been steadily
adopted albeit with a limited set of lesions and less favor-
able results when compared with the Cox maze proce-
dure.1-4 Electrophysiologists (EP) have dramatically
evolved as well from the original description of focal
pulmonary vein (PV) triggers of ablation, albeit with
poorer success rates than surgical ablations and with the
need for multiple procedures, especially in the presence
of persistent AF (P-AF) and long-standing persistent AF
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The Journal of Thoracic and Cardiovascular SurIn particular, there has been an increasing awareness
that PV isolation alone could not suffice for an effective
treatment of AF, especially in this specific subset of pa-
tients: surgical ablation per se could potentially offer an ex-
tensive and effective PV and left atrial isolation, while EP
approaches could allow for tailored additional lesions to
achieve durable results even in LSP-AF.7
We therefore aimed at combining a minimally invasive
surgical and catheter-based approach to merge respective
advantages and to reduce drawbacks of each procedure in
a sequential, staged hybrid fashion.METHODS
Study Population
From November 2006 to September 2011, 36 consecutive patients
with either P-AF (n ¼ 8, 22.2%) or LSP-AF (n ¼ 28, 77.8%) were pro-
spectively enrolled. As per Heart Rhythm Society (HRS) recommenda-
tions,8 inclusion criteria for stand-alone AF ablation were patients
with P-AF/LSP-AF with refractoriness to at least 1 antiarrhythmic
drug (either class I or III) and without any concomitant heart disease.
Exclusion criteria were previous cardiac surgery, previous catheter abla-
tion for AF treatment, and left atrial–anteroposterior diameter greater
than 60 mm. A detailed breakdown of patient characteristics is outlined
in Table 1; in particular, mean left atrial–anteroposterior dimension was
50.3  5.5 mm, and average AF duration was 72.8 months (range, 7-240
months).
As per the study protocol, patients underwent first an endoscopic, epi-
cardial surgical ablation with intraoperative assessment of the lesion setgery c December 2012
Abbreviations and Acronyms
AF ¼ atrial fibrillation
EP ¼ electrophysiologic (electrophysiologist)
HRS ¼ Heart Rhythm Society
LSP-AF ¼ long-standing persistent atrial fibrillation
P-AF ¼ persistent atrial fibrillation
PV ¼ pulmonary vein




Sfollowed by an EP evaluation and potential ‘‘touch-up’’ between 30 and 45
days postoperatively in a sequential, staged fashion.
The study protocol was approved by the Institutional Review Board and
Ethical Committee (No. NP1076) of the University of Brescia Medical
School.
First Step—Surgical Procedure
All patients underwent a routine preoperative evaluation, including
3-dimensional computed tomographic scan reconstruction, to obtain a de-
tailed preoperative plan, in particular with respect to PV anatomy and
variations.
The surgical ablation consisted of a closed-chest, right-sided monolat-
eral approach to deliver a continuous lesion encircling the origin of all
PVs and the posterior aspect of the left atrium en bloc (‘‘box’’ lesion set)
as previously described.9 In particular, care was taken during pericardial
opening to stay at least 2.5 to 3 cm away from the phrenic nerve so as to
minimize the incidence of postoperative phrenic nerve palsy and right di-
aphragm elevation. Of note, an extensive removal of the epicardial fat, es-
pecially at the level of the Waterston groove and the roof of the left atrium,
was performed before energy delivery in all patients. In fact, this maneuver
yields benefits both in terms of removal of ganglionic plexi and as better
adherence of the ablation probe with the atrial tissue and therefore im-
proved energy penetration. The ablation device used is a temperature-
controlled, monopolar radiofrequency device with suction adherence and
internal cooling (Cobra Adhere XL; Estech, San Ramon, Calif). The Cobra
Adhere XL is an ablation probe with CE mark and US investigational de-
vice exemption investigation (April 2012). The device is set at a maximum
power limit of 150 watts with a temperature control limit of 80C. A proper
adherence of the probe with the epicardial tissue occurs at values around
500 mm Hg of negative pressure; then, energy is delivered and ablation
continued for a 120-second ablation time. All electrodes (10 segments, 5
proximal and 5 distal) of the Cobra Adhere XL must be activated to allow
for continuous box lesions. Either the proximal (at the level of the trans-
verse sinus down to the left atrial appendage) or the distal ones (at the level
of the oblique sinus) are sequentially activated. It is of utmost importance to
deliver multiple ablations (at least twice per proximal or distal segment) on
the epicardial surface to achieve an effective isolation. Moreover, an exten-
sive overlapping is performed at the level of theWaterston groove to ensure
the ‘‘closure’’ of the box lesion.
At the completion of the surgical ablation, intraoperative assessment is
performed according to conventional EP parameters to demonstrate en-
trance and/or exit block across the box lesion, as per HRS recommenda-
tions.8 The PVs were monitored for reconduction 20 minutes after the
initial PV isolation. The study protocol mandated the achievement at least
of unidirectional block through the box lesion; if this end point was unmet,
additional ablations were delivered until either entry or entry block
(or both) were obtained.
The protocol outlined was used in all patients of the current series. A 6F
decapolar electrode endocardial catheter (P-Supra CS; Biosense Webster,
Diamond Bar, Calif) that has been previously positioned in the EP labora-
tory at the level of the coronary sinus is connected to an EP workstation.The Journal of Thoracic and CarA tetrapolar EP catheter (Avail, Josephson Curve, type A; Biosense Web-
ster) is then introduced through a port and advanced epicardially within the
box lesion (at the level of the right PVs and the roof of the left atrium) and
connected as well to the EP workstation. As depicted in Figures 1, A, and 2,
A, the catheter within the box lesion is used as a pacing probewhile sensing
with the catheter in the coronary sinus (exit block) or vice versa (entrance
block). In either instance, the maximum pacing output is 20 mA.
At the end of the surgical procedure, an implantable loop recorder
(Reveal XT, Medtronic, Inc, Minneapolis, Minn) is implanted in all
patients.
Postoperative Management
Postoperative pharmacologic management included the following:
Antiarrhythmic protocol. The antiarrhythmic protocol was
mostly based on amiodarone intake (or sotalol in case of contraindication
for amiodarone intake) for at least 3 months after the procedure.
Anticoagulation protocol. The anticoagulation protocol was
maintained for at least 3 months after the procedure. In case of stable sinus
rhythm, after an echocardiographic evaluation to rule out potential atrial
stasis or thrombus in the left atrium, anticoagulation was withdrawn and
aspirin started.
Moreover, given the potential inflammatory subset after ablation,10 all
patients received steroid intake after the first (surgical) step by means of
prednisone 25 mg per day for 1 week, then tapered to 12.5 mg for the sec-
ond week, finally to 6.25 mg for the third week, and then withdrawn.
After the surgical ablation, a blanking period of 3 months was estab-
lished before rhythm outcome was analyzed. Rhythm outcome was as-
sessed by data analysis of the Reveal XT on a monthly basis to rule out
potential AF recurrences and relative burden. Stable sinus rhythmwas con-
sidered as the absence of AF episodes lasting more than 5 minutes and an
overall burden of 0.5% of time spent in AF on a monthly basis, as previ-
ously reported.11,12 Data were obtained via the CareLink Network
(Medtronic, Inc), which allows for online storage and retrieval of data
without the need for an outpatient visit.
Second Step—EP Evaluation
The study protocol mandated that all patients undergo a staged catheter
procedure 30 to 45 days after the surgical ablation to assess the durability of
conduction block and to deliver additional ablation lesions via a transcath-
eter route if required. At a minimum, the treatment protocol required that
any gaps in the box lesion be closed by endocardial ablation. In all cases
the Cartomerge (Biosense Webster) system was used for electroanatomic
reconstruction. Noninducibility of AF and atrial flutter was also evaluated
by atrial burst pacing.RESULTS
First Step—Surgical Procedure
The closed-chest surgical ablation was successfully
completed in all patients without any intraoperative compli-
cations. Mean ablation and overall procedural times were
31  7 minutes and 80  7 minutes, respectively. Ablation
was performed as previously outlined in the Methods
section. At a minimum, unidirectional block had to be con-
firmed; documented intraoperative exit block was achieved
in 100% of patients whereas entrance blockwas achieved in
88.8% (32/36) of patients.
No patients required a stay in the intensive care unit, and
no complications occurred during the postoperative stay
(mean duration, 4  1.8 days). In particular, the incidence
of late coronary events (especially to the circumflex artery)diovascular Surgery c Volume 144, Number 6 1461
TABLE 1. Preoperative characteristics
Age, y (mean  SD) 62.3  10
Female gender, n (%) 19 (52.7%)
Diabetes mellitus, n (%) 7 (19.4%)
Hypertension, n (%) 15 (41.6%)
No. of failed AADs 1.9  0.4
AF type
Persistent, n (%) 8 (22.2%)
Long-standing persistent, n (%) 28 (77.8%)
AF duration, mo (mean and range) 72.8 (7-240)
LA size, mm (mean  SD) 50.3  5.5
LVEF,% (mean  SD) 52.5  3.3
AADs, Antiarrhythmic drugs; AF, atrial fibrillation; LA, left atrial; SD, standard
deviation; LVEF, left ventricular ejection fraction.




Sor right hemidiaphragm elevation was 0%. Hospital mortal-
ity was 0%.Second Step—EP Evaluation
After a postoperative interval of 33  2 days, all patients
underwent an EP evaluation: bidirectional (entrance–exit
block) was confirmed in 83.3% (30/36) of patients with
PV reconnections observed in 16.7% (6/36), which were
obviously treated percutaneously. As previously outlined,
noninducibility of AF and atrial flutter was evaluated by
atrial burst pacing.
Overall, transcatheter lesions were performed in 61.1%
(22/36) of the patients. Besides gaps in the box lesion (6/36
patients, 16.7%), additional ablations were mostly targeted
at the cavotricuspid isthmus (owing to inducible or a posi-
tive history of typical flutter) in 58.3% (21/36) of the
patients, whereas complex atrial fractionated electrograms
were targeted at 16.6% (6/36) of patients. Finally, in
38.8% (14/36) of patients, firing foci within the PVs could
be identified during the EP evaluation, and an additional PV
antral line was performed even in the presence of an effec-
tive box ablation line (with block confirmation), so as to
provide an additional ‘‘barrier’’ in case of potential later
PV reconnection.
In case of box lesion set evaluation only (transseptal punc-
ture and lesion test), mean procedural time was 18  2
minutes, and additional ablations time was 25  4 minutes.
No atypical left-sided flutter could be induced and there-
fore no connecting lesion to the mitral anulus was
performed.Midterm Follow-up
Patients were observed for a mean follow-up of 30
months (range, 1-58 months; median, 28 months) and
rhythm outcomes were monitored on a monthly basis via
the Reveal XT and CareLink Network. Of note, only 1 pa-
tient had a postoperative follow-up of 1 month, whereas
all other patients in the series had been evaluated for at least
8 months. Stable sinus rhythm was considered as the1462 The Journal of Thoracic and Cardiovascular Surabsence of AF episodes lasting more than 5 minutes and
an overall burden of 0.5% of time spent in AF on a monthly
basis, as previously outlined11,12; 91.6% (33/36) of patients
are in sinus rhythm with 77.7% (28/36) of these patients off
antiarrhythmic drugs and 88.8% (32/36) free from
anticoagulation (after echocardiographic evaluation to
rule out potential atrial stasis or thrombus in the left
atium). Of note, the long-term incidence of left atrial flutter
was 0%.
DISCUSSION
The challenges in the treatment of P-AF have demon-
strated the drawbacks of both the surgical and the percuta-
neous approach. From the surgical standpoint, the
invasiveness of the Cox maze procedure has hampered its
wide adoption, despite the relevant success rates; transcath-
eter procedures instead are less-invasive procedures that
are, however, associated with poor outcomes even after sev-
eral ablations at long-term follow-up, especially in the pres-
ence of LSP-AF.5
The reason to merge surgical and percutaneous tech-
niques and technologies in a hybrid fashion is therefore to
reduce the complications and drawbacks of either procedure
while improving the results of both approaches.
When a hybrid approach is used, it can be performed as
either a concomitant or staged procedure, as previously de-
scribed.7,13-15 We decided to perform surgery first inasmuch
as it allows for an extensive isolation of the PV and the
posterior aspect of the left atrium, thereby excluding not
only the potential focal triggers located within the PVs
but also the macroreentrant circuits and the fragmented
potential, which are usually located in this anatomic
region. From the EP perspective, such surgical
radiofrequency ablation yields considerable advantages
since the recent HRS consensus statement also
recommends that radiofrequeny power be reduced when
treating the posterior left atrium to reduce the risk of
potential collateral damage to the esophagus. Therefore,
this procedural limitation could represent a drawback of
transcatheter ablation and potentially jeopardize success.
Instead, such risk can be mitigated by the surgical box
lesion set.
Moreover, from the surgical standpoint, if deemed neces-
sary it is possible to easily create an additional intercaval le-
sion (from the superior to the inferior vena cava)
epicardially, thereby entirely avoiding the risk associated
with phrenic nerve palsy after a transcatheter approach,
which is estimated to occur in around 6% of cases.16
As previously outlined in the Methods section, assess-
ment of PV anatomy is of utmost importance from both
the surgical and the EP perspectives. Before the surgical
procedure, any relevant anatomic variation can be ruled
out because of the presence of an additional right inferior
PV that may inadvertently be damaged during the openinggery c December 2012
FIGURE 1. Schematic drawing (A) depicting a test of exit conduction block by means of pacing within the box lesion and sensing at the level of the cor-
onary sinus. B, Absence of correlation between the pacing stimuli at the level of the pulmonary veins (arrowheads) and the surface electrocardiogram
(arrows). SVC, Superior vena cava; IVC, inferior vena cava; RSPV, right superior pulmonary vein; LSPV, left superior pulmonary vein; RA, right atrium.




Sof the pericardial reflection to the oblique sinus. Moreover,
from the EP standpoint, the presence of a common ostial
trunk may represent a technical challenge in several in-
stances that could be easily overcome by a surgical box le-
sion set.
The collaboration with EPs is extremely important for
surgeons also in terms of intraoperative validation of the
surgical ablation, thanks to the use of EP tools and end
points. In our experience, it has consistently improved the
quality of epicardial unipolar radiofrequency ablation, de-
spite the potential concern in terms of efficacy of such an
approach when achieving an effective conduction block.
Instead, the intraoperative EP assessment allowed for a tai-
lored delivery of radiofrequency applications, until at least
entrance and/or exit block was demonstrated, as per HRSThe Journal of Thoracic and Carrecommendations.8 As reported, we could achieve
bidirectional block in 88.8% of patients and exit block in
100% of patients.
The interdisciplinary collaboration is also beneficial for
EPs. Even though the current study did not aim at compar-
ing the hybrid approach with other techniques (eg, trans-
catheter ablation alone), there is also a potential
advantage in terms of reduced fluoroscopy and overall pro-
cedural time.
The treatment of the left atrial appendage bymeans of ex-
clusion/excision is one of the cornerstones of the maze pro-
cedure and is associated with a reduced incidence of late
thromboembolic events. To date, there are no safe and
widely validated techniques and technologies for exclusion
of the left atrial appendage via a right monolateraldiovascular Surgery c Volume 144, Number 6 1463
FIGURE 2. Schematic drawing (A) depicting test of entrance conduction block by means of pacing at the level of the coronary sinus and sensing within the
box. B, Pacing at the level of the coronary sinus (arrowheads) with local capture (arrows) albeit without any recorded potentials within the box lesion
(circles). SVC, Superior vena cava; IVC, inferior vena cava; RSPV, right superior pulmonary vein; LSPV, left superior pulmonary vein; RA, right atrium.




Sapproach, and we therefore avoided any left atrial append-
age treatment. Obviously, the possibility to continuously
monitor the heart rhythm thanks to the implantable loop re-
corder allowed for a safe withdrawal of anticoagulation
therapy in patients with a low CHAD2-VASc2 score and sta-
ble sinus rhythm.
In our experience, the possibility to delay the EP assess-
ment from the surgical procedure allowed us to achieve im-
portant insights. First, it allowed for further ‘‘evolution’’ of
the ablative lesions (usually occurring within a few weeks)
to avoid false positive results in terms of early inducible ar-
rhythmias.17 Then, false negatives may be minimized inas-
much as acute demonstration of a bidirectional block could
only be transient and not confirmed by delayed testing at1464 The Journal of Thoracic and Cardiovascular Sur1 month after surgery. In our series, for example, 2 patients
‘‘lost’’ acute bidirectional block while showing only exit
block during the staged EP evaluation. Moreover, it was
possible to perform tailored additional endocardial abla-
tions (as depicted in the Results), which could have ac-
counted for the excellent results even at 30 months’
follow-up time.
Finally, the use of an implantable loop recorder allowed
for continuous monitoring of heart rhythm and overcame
the potential bias and drawbacks of spot or Holter electro-
cardiograms or even transtelephonic monitoring.
Inasmuch as a consistent percentage of patients (around
40%) did not require any additional touch-up during the
second EP evaluation, this subgroup of patients may havegery c December 2012
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Sundergone unnecessary EP procedures after the surgical ab-
lation. Nevertheless, the lack of clinical data with this ap-
proach led us to have all patients undergoing the
sequential staged EP evaluation regardless of the rhythm
outcome (with the implantable loop recorder). In fact, this
approach allowed for an evaluation of the effectiveness of
the surgical ablation in our preliminary series of hybrid ab-
lations. We believe the protocol may be further adapted as
more data are gathered, especially in the presence of a con-
tinuously stable sinus rhythm after the surgical ablation,
which could therefore avoid the need for an additional EP
evaluation.
The current study yields several limitations, especially in
terms of the limited number of patients enrolled, and further
evaluation of the sequential staged surgical–EP approach on
a larger series of patients with a longer follow-up is war-
ranted. Nevertheless, the current study proved the safety,
feasibility, and preliminary efficacy of a novel therapeutic
strategy for the treatment of P-AF and LSP-AF.
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Dr Charles R. Bridges (Charlotte, NC). I have a couple of
questions. Could you provide more details of exactly how sinus
rhythmwas documented at 30 months and at each of the individual
time points? What modality did you use? As you know, electrocar-
diography, for example, will certainly miss a large percentage of
patients who have ongoing paroxysmal AF.
DrMuneretto. Thank you for your question. As I showed in the
slides, all patients received a continuous monitoring loop recorder.
We analyzed the rhythms as a continuous phase for the entire fol-
low-up period by 1 month, 3 months, 6 months, 9 months, 12
months, and every 3 months. I think that our results should be eval-
uated also according to that, because until now, the majority of pa-
pers published in the literature use spot electrocardiograms or spot
Holter monitoring to assess recurrences, and obviously the use of
continuous monitoring systems is much more specific for that.diovascular Surgery c Volume 144, Number 6 1465
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